Welcome to our dedicated page for Quest Diagnostics SEC filings (Ticker: DGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medicare reimbursement shifts, intricate lab test coding, and a steady stream of acquisitions make Quest Diagnostics’ disclosures anything but light reading. If you have ever Googled, “How to read Quest Diagnostics’ 10-K annual report” or “Quest Diagnostics SEC filings explained simply,” you already know each report buries critical payer-mix data, segment margins, and CLIA compliance notes inside hundreds of pages.
Stock Titan’s AI-powered analysis turns that maze into a map. Every Quest Diagnostics annual report 10-K simplified, each Quest Diagnostics quarterly earnings report 10-Q filing distilled into revenue drivers, and all Quest Diagnostics 8-K material events explained appear here the moment EDGAR posts. Ask, “What does Quest Diagnostics report in their SEC filings?” and you’ll find plain-English summaries, red-flag alerts, and linked schedules. Our dashboard even flags the Quest Diagnostics proxy statement executive compensation tables so pay packages can be reviewed alongside performance trends.
Keeping tabs on leadership confidence? We surface Quest Diagnostics insider trading Form 4 transactions and deliver Quest Diagnostics Form 4 insider transactions real-time so you never miss a trade. Use the platform to:
- Compare revenue swings between Diagnostic Information Services and Drug Monitoring segments
- Review Quest Diagnostics earnings report filing analysis with AI commentary
- Track Quest Diagnostics executive stock transactions Form 4 ahead of material announcements
From understanding Quest Diagnostics SEC documents with AI to spotting compliance risks before they hit the headlines, our comprehensive coverage and real-time alerts provide the clarity professionals need.
Quest Diagnostics Inc. (DGX) has filed a Form 144 indicating an intended sale of 8,269 common shares through Fidelity Brokerage Services.
- Aggregate market value: $1,384,230.60 (based on the market price on the filing date).
- Percentage of shares outstanding: approx. 0.0074 % of the 111,823,441 shares outstanding — an immaterial level.
- Anticipated sale date: 07 / 30 / 2025 on the NYSE.
- Source of shares: options granted on 18 Feb 2019 (3,045 shares) and 18 Feb 2020 (5,224 shares); cash was paid upon exercise.
No shares were sold during the prior three months, and the signer represents no undisclosed adverse information. The filer’s name, relationship to the issuer, and 10b5-1 plan data were not disclosed in the excerpt.
FAQ
What is the current stock price of Quest Diagnostics (DGX)?
What is the market cap of Quest Diagnostics (DGX)?
